Heartbeat Desk
Incepta Pharmaceuticals has partnered with UK-based biomedical company ViraCorp in order to develop a Covid-19 vaccine that can be administered using a nasal spray.
The vaccine would require cold chain transport, which is also required for other Covid vaccines. The nasal mode of delivery would reduce training requirements for vaccination drives and it also boasts other advantages, according to a press release cited in media reports.
“Having a vaccine which can be transported easily and administered through a nasal delivery system reduces the heavy infrastructure and training requirements of a vaccination drive and will help ensure that the vaccine can reach some of the world’s most remote communities,” Lancaster virologist Dr Muhammad Munir, on whose work the vaccine is based, said in the press release.
Dr Abdul Muktadir, chairman and managing director of Incepta Vaccine Ltd, also highlighted the convenience of the vaccine nasal spray.
ViraCorp CEO Jon Chadwick spoke of the logistical and financial benefits of the partnership with Incepta in the development of the nasal Covid vaccine.
A timeline for when the vaccine may become available was not disclosed.
Discussion about this post